Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

INTRODUCTION: Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but resistance develops. This study assessed the maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activity of ceritinib, a novel ALK inhibitor (ALKi), in J...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Nishio, Makoto, Murakami, Haruyasu, Horiike, Atsushi, Takahashi, Toshiaki, Hirai, Fumihiko, Suenaga, Naoko, Tajima, Takeshi, Tokushige, Kota, Ishii, Masami, Boral, Anthony, Robson, Matthew, Seto, Takashi
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467585/
https://ncbi.nlm.nih.gov/pubmed/26020125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000566
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados